A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of beta-amyloid load in an AD cohort
Steve Pedrini, Veer B Gupta, Eugene Hone, James Doecke, Sid O'Bryant, Ian James, Ashley I Bush, Christopher C Rowe, Victor L Villemagne, David Ames, Colin L Masters, Ralph N Martins
Scientific Reports | NATURE PUBLISHING GROUP | Published : 2017
We thank all the participants who took part in this study and the clinicians who referred participants. The AIBL study (www.AIBL.csiro.au) is a collaboration between CSIRO, Edith Cowan University (ECU), National Ageing Research Institute (NARI), The Florey Institute of Neuroscience and Mental Health (FINMH) and Austin Health. It also received support from Hollywood Private Hospital, CogState Ltd., and Sir Charles Gairdner Hospital and funding support from Alzheimer's Australia (AA), CSIRO, the Science and Industry Endowment Fund, McCusker Alzheimer's Research Foundation, Brightfocus, USA and the WA Dept. of Health, as well as industry sources. The authors acknowledge the financial support of the Cooperative Research Centre (CRC) for Mental Health, which is an Australian Government Initiative. Pfizer International has provided financial support to assist with analysis of blood samples and to further the AIBL research program.